公开(公告)号：US20250000070A1

公开(公告)日：2025-01-02

申请号：US18766891

申请日：2024-07-09

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lynn Macdonald ,  Andrew J. Murphy ,  Naxin Tu ,  Vera Voronina ,  Cagan Gurer

IPC: A01K67/0278 ,  C07K14/705 ,  C07K14/73 ,  C07K14/74 ,  C12N5/0735 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/85

Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8α, CD8β), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.

公开(公告)号：US12180272B2

公开(公告)日：2024-12-31

申请号：US17666107

申请日：2022-02-07

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Tong Zhang ,  Erica Pyles ,  Michael Rosconi ,  Nina Liu ,  Supriya Patel ,  Eric Smith ,  Andrew Murphy ,  Chia-Yang Lin ,  Samuel Davis

IPC: C07K16/00 ,  A61K39/395 ,  A61K47/68 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  C12P21/08 ,  C07K1/00

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

公开(公告)号：US20240425609A1

公开(公告)日：2024-12-26

申请号：US18708256

申请日：2022-11-09

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Yang SHEN ,  Bei WANG ,  Naga Suhasini AVVARU ,  Chia-Yang LIN ,  Andrew J. MURPHY ,  Aynur HERMANN ,  Jee H. KIM

IPC: C07K16/28 ,  A61K39/00 ,  A61P37/06 ,  G01N33/68

Abstract: The present disclosure relates to molecules capable of binding to both CD20 and PD1, as well as pharmaceutical compositions comprising such molecules and methods of use thereof.

公开(公告)号：US20240424145A1

公开(公告)日：2024-12-26

申请号：US18734482

申请日：2024-06-05

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lynn MacDonald ,  Naxin Tu ,  Cagan Gurer ,  Sean Stevens ,  Andrew J. Murphy

IPC: A61K49/00 ,  A01K67/0276 ,  A01K67/0278 ,  C07K14/735 ,  G01N33/50

Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.

公开(公告)号：US12163192B2

公开(公告)日：2024-12-10

申请号：US18096232

申请日：2023-01-12

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Joshua Backman ,  Aris Baras

IPC: C12Q1/6883 ,  A61K31/192 ,  A61K31/616 ,  A61P9/14 ,  C12N15/10 ,  C12Q1/6827

Abstract: Methods of treating patients having varicose veins, methods of identifying subjects having an increased risk of developing varicose veins, and methods of diagnosing varicose veins in a human subject, comprising detecting the presence of Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) predicted loss-of-function variant nucleic acid molecules and polypeptides in a biological sample from the patient or subject, are provided herein.

公开(公告)号：US12162943B2

公开(公告)日：2024-12-10

申请号：US17064393

申请日：2020-10-06

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Joel H. Martin ,  Tammy T. Huang ,  Jeanette L. Fairhurst ,  Nicholas J. Papadopoulos ,  George D. Yancopoulos

IPC: A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

Abstract: The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-IL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-IL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.

公开(公告)号：US20240400632A1

公开(公告)日：2024-12-05

申请号：US18808781

申请日：2024-08-19

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Jiaxi WU ,  Tong ZHANG ,  Maria del Pilar MOLINA-PORTELA ,  Eric SMITH ,  Chia-Yang LIN ,  Thomas Craig MEAGHER

IPC: C07K14/55 ,  A61K35/17 ,  A61K38/00 ,  A61K38/20 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K14/74

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

公开(公告)号：US12157916B2

公开(公告)日：2024-12-03

申请号：US17395566

申请日：2021-08-06

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Ruoyu Zhang ,  Wei Keat Lim ,  Gurinder Atwal

IPC: C12Q1/6869 ,  C12Q1/6806 ,  G16B20/20 ,  G16B30/10 ,  G16B30/20 ,  G16B40/00 ,  G16B40/20

Abstract: The present disclosure provides methods of identifying unreliable biological samples that may be mislabeled or contaminated, by determining the heteroplasmy and homoplasmy of mitochondrial DNA present in the biological samples.

公开(公告)号：US12157758B2

公开(公告)日：2024-12-03

申请号：US17496263

申请日：2021-10-07

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Samuel Davis ,  Eric Smith ,  Douglas MacDonald ,  Kara Louise Olson

IPC: A61K39/395 ,  C07K1/22 ,  C07K16/24 ,  C07K16/28 ,  C07K16/46 ,  A61K39/00

Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.

公开(公告)号：US20240390489A1

公开(公告)日：2024-11-28

申请号：US18674399

申请日：2024-05-24

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Robert C. PORDY ,  Xiaobing QIAN ,  Stephen DONAHUE

IPC: A61K39/395 ,  A61K39/00 ,  C07K14/47 ,  C07K14/475 ,  C07K16/22

Abstract: The disclosure provides compositions, kits, and methods of using a GDF-8 inhibitor to increase lean muscle mass. In embodiments, a GDF-8 inhibiter is an antibody or antigen binding fragment thereof that specifically binds GDF-8. In embodiments, a method comprises providing an exercise regimen for the subject, and administering a composition comprising an effective amount of a GDF-8 inhibitor.